Zobrazeno 1 - 10
of 689
pro vyhledávání: '"tafenoquine"'
Autor:
Rimmy Nandal, Davinder Kumar, Navidha Aggarwal, Virender Kumar, Balasubramanian Narasimhan, Rakesh Kumar Marwaha, Prabodh Chander Sharma, Surender Kumar, Nitin Bansal, Hitesh Chopra, Aakash Deep
Publikováno v:
EXCLI Journal : Experimental and Clinical Sciences, Vol 23, Pp 672-713 (2024)
Malaria has developed as a serious worldwide health issue as a result of the introduction of resistant Plasmodium species strains. Because of the common chemo resistance to most of the existing drugs on the market, it poses a severe health problem an
Externí odkaz:
https://doaj.org/article/202fcb5419494dc49082aaec1efb65a6
Autor:
Raman Sharma, Hema Sharma, Siôn Jones, Isabelle Borghini-Fuhrer, Gonzalo J. Domingo, Rachel A. Gibson, Katie Rolfe, Lionel Tan, Ioana Gabriela Fiţa, Chao Chen, Panayota Bird, Anup Pingle, Stephan Duparc
Publikováno v:
Malaria Journal, Vol 23, Iss 1, Pp 1-6 (2024)
Abstract A single 300 mg dose of tafenoquine (an 8-aminoquinoline), in combination with a standard 3-day course of chloroquine, is approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged
Externí odkaz:
https://doaj.org/article/8e4d2be46a454fcaaae784e04ad2fa94
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
BackgroundPlasmodium vivax malaria has been one of the most troublesome diseases in the Democratic People’s Republic of Korea (DPRK). Given that a majority of malaria cases are concentrated near the demilitarized zone, concerted elimination efforts
Externí odkaz:
https://doaj.org/article/a3f42ea2b32247fea927ee63640b0f75
Publikováno v:
Pharmaceutics, Vol 16, Iss 9, p 1124 (2024)
Tafenoquine (TQ) is a new 8-aminoquinoline antimalarial drug developed by the US Army for Plasmodium vivax malaria treatment. Modeling and simulation are essential tools for drug development and improving rationality in pharmacotherapy, and different
Externí odkaz:
https://doaj.org/article/7de46518574948a3b83e668cccbc5134
Autor:
James A Watson, Robert J Commons, Joel Tarning, Julie A Simpson, Alejandro Llanos Cuentas, Marcus VG Lacerda, Justin A Green, Gavin CKW Koh, Cindy S Chu, François H Nosten, Richard N Price, Nicholas PJ Day, Nicholas J White
Publikováno v:
eLife, Vol 13 (2024)
In our recent paper on the clinical pharmacology of tafenoquine (Watson et al., 2022), we used all available individual patient pharmacometric data from the tafenoquine pre-registration clinical efficacy trials to characterise the determinants of ant
Externí odkaz:
https://doaj.org/article/a448849101ae42ba942170feabc3d8bf
Autor:
Raman Sharma, Chao Chen, Lionel Tan, Katie Rolfe, Ioana-Gabriela Fiţa, Siôn Jones, Anup Pingle, Rachel A Gibson, Navin Goyal, Hema Sharma, Panayota Bird
Publikováno v:
eLife, Vol 13 (2024)
A single 300 mg dose of tafenoquine, in combination with chloroquine, is currently approved in several countries for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged ≥16 years. Recently, however, Watson et al. s
Externí odkaz:
https://doaj.org/article/b532a7338996414085af7657c6237fea
Publikováno v:
mSystems, Vol 8, Iss 6 (2023)
ABSTRACT Staphylococcus aureus is an important human pathogen that often leads to hospital-acquired and community-acquired infections. The appearance of methicillin-resistant S. aureus (MRSA) has made the treatment extremely challenging. There is an
Externí odkaz:
https://doaj.org/article/e484d6a8406940b9b72ee3e4a9ca5a8e
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Dana G. Mordue, Synthia J. Hale, William E. Dennis, Chau V. Vuong, Xiu-Min Li, Nan Yang, Gary P. Wormser
Publikováno v:
Pathogens, Vol 12, Iss 9, p 1113 (2023)
Previous studies of mice infected with Babesia microti have shown that a single dose of tafenoquine administered orally is extremely effective at decreasing microscopically detectable parasitemia. However, a critical limitation of studies to date is
Externí odkaz:
https://doaj.org/article/febb7a0670c543338f586da40c931e83
Autor:
James A Watson, Robert J Commons, Joel Tarning, Julie A Simpson, Alejandro Llanos Cuentas, Marcus VG Lacerda, Justin A Green, Gavin CKW Koh, Cindy S Chu, François H Nosten, Richard N Price, Nicholas PJ Day, Nicholas J White
Publikováno v:
eLife, Vol 11 (2022)
Tafenoquine is a newly licensed antimalarial drug for the radical cure of Plasmodium vivax malaria. The mechanism of action and optimal dosing are uncertain. We pooled individual data from 1102 patients and 72 healthy volunteers studied in the pre-re
Externí odkaz:
https://doaj.org/article/f5567952f4604510b3632a25a317789f